US biotech Merida Biosciences has launched with $121m in Series A financing to develop therapeutics targeting disease-causing antibodies in autoimmune diseases and allergies. The financing round ...

Merida Biosciences, a startup formed by venture capital firm Third Rock Ventures, emerged from stealth Tuesday, revealing $121 million in financing and a lead program for a common autoimmune ...

April 08, 2025--(BUSINESS WIRE)--Merida Biosciences, a biotechnology company pioneering a new class of precision therapeutics designed to selectively and durably eliminate the pathogenic antibody ...

Merida Therapeutics was seeded by Third Rock back in 2022, when the biotech’s co-founder and chief scientific officer Dario Gutierrez, Ph.D., was entrepreneur-in-residence at the VC firm.

Series A financing co-led by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures Merida Biosciences, a biotechnology company pioneering a new class of precision therapeutics designed ...